HEADER NUCLEAR PROTEIN/ANTAGONIST 23-FEB-18 6CHW TITLE ESTROGEN RECEPTOR ALPHA Y537S COVALENTLY BOUND TO ANTAGONIST H3B-5942. COMPND MOL_ID: 1; COMPND 2 MOLECULE: ESTROGEN RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: ER,ER-ALPHA,ESTRADIOL RECEPTOR,NUCLEAR RECEPTOR SUBFAMILY 3 COMPND 5 GROUP A MEMBER 1; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: ESR1, ESR, NR3A1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS NUCLEAR HORMONE RECEPTOR, COVALENT ANTAGONIST, ACTIVATING MUTATION, KEYWDS 2 BREAST CANCER, NUCLEAR PROTEIN, NUCLEAR PROTEIN-ANTAGONIST COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR N.A.LARSEN REVDAT 5 26-FEB-20 6CHW 1 REMARK REVDAT 4 12-SEP-18 6CHW 1 JRNL REVDAT 3 29-AUG-18 6CHW 1 JRNL REVDAT 2 25-JUL-18 6CHW 1 JRNL REVDAT 1 21-MAR-18 6CHW 0 JRNL AUTH X.PUYANG,C.FURMAN,G.Z.ZHENG,Z.J.WU,D.BANKA,K.AITHAL, JRNL AUTH 2 S.AGOULNIK,D.M.BOLDUC,S.BUONAMICI,B.CALEB,S.DAS,S.ECKLEY, JRNL AUTH 3 P.FEKKES,M.H.HAO,A.HART,R.HOUTMAN,S.IRWIN,J.J.JOSHI,C.KARR, JRNL AUTH 4 A.KIM,N.KUMAR,P.KUMAR,G.KUZNETSOV,W.G.LAI,N.LARSEN, JRNL AUTH 5 C.MACKENZIE,L.A.MARTIN,D.MELCHERS,A.MORIARTY,T.V.NGUYEN, JRNL AUTH 6 J.NORRIS,M.O'SHEA,S.PANCHOLI,S.PRAJAPATI,S.RAJAGOPALAN, JRNL AUTH 7 D.J.REYNOLDS,V.RIMKUNAS,N.RIOUX,R.RIBAS,A.SIU,S.SIVAKUMAR, JRNL AUTH 8 V.SUBRAMANIAN,M.THOMAS,F.H.VAILLANCOURT,J.WANG,S.WARDELL, JRNL AUTH 9 M.J.WICK,S.YAO,L.YU,M.WARMUTH,P.G.SMITH,P.ZHU,M.KORPAL JRNL TITL DISCOVERY OF SELECTIVE ESTROGEN RECEPTOR COVALENT JRNL TITL 2 ANTAGONISTS FOR THE TREATMENT OF ER ALPHAWTAND ER JRNL TITL 3 ALPHAMUTBREAST CANCER. JRNL REF CANCER DISCOV V. 8 1176 2018 JRNL REFN ESSN 2159-8290 JRNL PMID 29991605 JRNL DOI 10.1158/2159-8290.CD-17-1229 REMARK 2 REMARK 2 RESOLUTION. 1.89 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.8.0158 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.89 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 44.47 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 3 NUMBER OF REFLECTIONS : 22475 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.202 REMARK 3 R VALUE (WORKING SET) : 0.200 REMARK 3 FREE R VALUE : 0.257 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1216 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.89 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.94 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1601 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 100.0 REMARK 3 BIN R VALUE (WORKING SET) : 0.2400 REMARK 3 BIN FREE R VALUE SET COUNT : 79 REMARK 3 BIN FREE R VALUE : 0.3810 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1956 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 53 REMARK 3 SOLVENT ATOMS : 150 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 37.58 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.00000 REMARK 3 B22 (A**2) : 0.00000 REMARK 3 B33 (A**2) : 0.00000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.152 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.154 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.101 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 3.362 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.956 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.918 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2061 ; 0.019 ; 0.019 REMARK 3 BOND LENGTHS OTHERS (A): 1997 ; 0.005 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 2781 ; 2.043 ; 2.002 REMARK 3 BOND ANGLES OTHERS (DEGREES): 4624 ; 1.263 ; 3.005 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 251 ; 7.026 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 83 ;38.787 ;24.096 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 383 ;16.132 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 11 ;17.422 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 322 ; 0.145 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2212 ; 0.011 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): 394 ; 0.002 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 992 ; 3.586 ; 3.542 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 991 ; 3.582 ; 3.538 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 1241 ; 5.019 ; 5.287 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): 1242 ; 5.018 ; 5.292 REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1068 ; 4.838 ; 4.008 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): 1069 ; 4.837 ; 4.009 REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): 1539 ; 6.729 ; 5.803 REMARK 3 LONG RANGE B REFINED ATOMS (A**2): 2437 ; 9.522 ;43.913 REMARK 3 LONG RANGE B OTHER ATOMS (A**2): 2438 ; 9.521 ;43.924 REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS REMARK 4 REMARK 4 6CHW COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 26-FEB-18. REMARK 100 THE DEPOSITION ID IS D_1000232796. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 25-OCT-14 REMARK 200 TEMPERATURE (KELVIN) : 120 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 21-ID-F REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9787 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RAYONIX MX225-HS REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-3000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 29591 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.750 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 15.40 REMARK 200 R MERGE (I) : 0.08500 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 8.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.75 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.81 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 15.90 REMARK 200 R MERGE FOR SHELL (I) : 0.88800 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 49.60 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.44 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 6-12% PEG 3350, 50-150 MM MGCL2, 0.1 M REMARK 280 IMIDAZOLE PH 7.1, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 65 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 -X,-Y,Z+1/2 REMARK 290 5555 Y,-X+Y,Z+1/6 REMARK 290 6555 X-Y,X,Z+5/6 REMARK 290 7555 Y,X,-Z+2/3 REMARK 290 8555 X-Y,-Y,-Z REMARK 290 9555 -X,-X+Y,-Z+1/3 REMARK 290 10555 -Y,-X,-Z+1/6 REMARK 290 11555 -X+Y,Y,-Z+1/2 REMARK 290 12555 X,X-Y,-Z+5/6 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 183.20933 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 91.60467 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 137.40700 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 45.80233 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 229.01167 REMARK 290 SMTRY1 7 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 7 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 183.20933 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 9 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 9 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 9 0.000000 0.000000 -1.000000 91.60467 REMARK 290 SMTRY1 10 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 10 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 10 0.000000 0.000000 -1.000000 45.80233 REMARK 290 SMTRY1 11 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 11 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 11 0.000000 0.000000 -1.000000 137.40700 REMARK 290 SMTRY1 12 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 12 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 12 0.000000 0.000000 -1.000000 229.01167 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 0.500000 -0.866025 0.000000 29.36750 REMARK 350 BIOMT2 2 -0.866025 -0.500000 0.000000 50.86600 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 45.80233 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A 809 LIES ON A SPECIAL POSITION. REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LEU A 462 CG CD1 CD2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 352 NE - CZ - NH1 ANGL. DEV. = 3.5 DEGREES REMARK 500 ARG A 412 NE - CZ - NH1 ANGL. DEV. = 3.3 DEGREES REMARK 500 ARG A 436 NE - CZ - NH1 ANGL. DEV. = 4.3 DEGREES REMARK 500 ARG A 503 NE - CZ - NH1 ANGL. DEV. = 3.5 DEGREES REMARK 500 LEU A 541 CA - CB - CG ANGL. DEV. = 14.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 417 -70.44 -48.33 REMARK 500 MET A 528 31.60 -146.98 REMARK 500 LYS A 529 127.32 59.32 REMARK 500 LYS A 531 46.44 14.13 REMARK 500 ASN A 532 62.02 7.92 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 CYS A 530 LYS A 531 147.61 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue F3D A 601 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 602 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 603 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 604 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue DMS A 605 DBREF 6CHW A 306 551 UNP P03372 ESR1_HUMAN 306 551 SEQADV 6CHW SER A 381 UNP P03372 CYS 381 ENGINEERED MUTATION SEQADV 6CHW SER A 417 UNP P03372 CYS 417 ENGINEERED MUTATION SEQADV 6CHW SER A 537 UNP P03372 TYR 537 ENGINEERED MUTATION SEQRES 1 A 246 LEU ALA LEU SER LEU THR ALA ASP GLN MET VAL SER ALA SEQRES 2 A 246 LEU LEU ASP ALA GLU PRO PRO ILE LEU TYR SER GLU TYR SEQRES 3 A 246 ASP PRO THR ARG PRO PHE SER GLU ALA SER MET MET GLY SEQRES 4 A 246 LEU LEU THR ASN LEU ALA ASP ARG GLU LEU VAL HIS MET SEQRES 5 A 246 ILE ASN TRP ALA LYS ARG VAL PRO GLY PHE VAL ASP LEU SEQRES 6 A 246 THR LEU HIS ASP GLN VAL HIS LEU LEU GLU SER ALA TRP SEQRES 7 A 246 LEU GLU ILE LEU MET ILE GLY LEU VAL TRP ARG SER MET SEQRES 8 A 246 GLU HIS PRO GLY LYS LEU LEU PHE ALA PRO ASN LEU LEU SEQRES 9 A 246 LEU ASP ARG ASN GLN GLY LYS SER VAL GLU GLY MET VAL SEQRES 10 A 246 GLU ILE PHE ASP MET LEU LEU ALA THR SER SER ARG PHE SEQRES 11 A 246 ARG MET MET ASN LEU GLN GLY GLU GLU PHE VAL CYS LEU SEQRES 12 A 246 LYS SER ILE ILE LEU LEU ASN SER GLY VAL TYR THR PHE SEQRES 13 A 246 LEU SER SER THR LEU LYS SER LEU GLU GLU LYS ASP HIS SEQRES 14 A 246 ILE HIS ARG VAL LEU ASP LYS ILE THR ASP THR LEU ILE SEQRES 15 A 246 HIS LEU MET ALA LYS ALA GLY LEU THR LEU GLN GLN GLN SEQRES 16 A 246 HIS GLN ARG LEU ALA GLN LEU LEU LEU ILE LEU SER HIS SEQRES 17 A 246 ILE ARG HIS MET SER ASN LYS GLY MET GLU HIS LEU TYR SEQRES 18 A 246 SER MET LYS CYS LYS ASN VAL VAL PRO LEU SER ASP LEU SEQRES 19 A 246 LEU LEU GLU MET LEU ASP ALA HIS ARG LEU HIS ALA HET F3D A 601 37 HET EDO A 602 4 HET EDO A 603 4 HET EDO A 604 4 HET DMS A 605 4 HETNAM F3D 4-[(2-{4-[(1E)-1-(1H-INDAZOL-5-YL)-2-PHENYLBUT-1-EN-1- HETNAM 2 F3D YL]PHENOXY}ETHYL)AMINO]-N,N-DIMETHYLBUTANAMIDE HETNAM EDO 1,2-ETHANEDIOL HETNAM DMS DIMETHYL SULFOXIDE HETSYN EDO ETHYLENE GLYCOL FORMUL 2 F3D C31 H36 N4 O2 FORMUL 3 EDO 3(C2 H6 O2) FORMUL 6 DMS C2 H6 O S FORMUL 7 HOH *150(H2 O) HELIX 1 AA1 LEU A 306 LEU A 310 5 5 HELIX 2 AA2 THR A 311 ALA A 322 1 12 HELIX 3 AA3 PRO A 336 ALA A 340 5 5 HELIX 4 AA4 SER A 341 ARG A 363 1 23 HELIX 5 AA5 THR A 371 SER A 395 1 25 HELIX 6 AA6 ARG A 412 LYS A 416 1 5 HELIX 7 AA7 GLY A 420 ASN A 439 1 20 HELIX 8 AA8 GLN A 441 SER A 456 1 16 HELIX 9 AA9 THR A 465 ALA A 493 1 29 HELIX 10 AB1 THR A 496 SER A 527 1 32 HELIX 11 AB2 PRO A 535 ASP A 545 1 11 SHEET 1 AA1 2 LYS A 401 ALA A 405 0 SHEET 2 AA1 2 LEU A 408 ASP A 411 -1 O LEU A 410 N LEU A 402 LINK SG CYS A 530 C11 F3D A 601 1555 1555 1.62 SITE 1 AC1 14 LEU A 346 THR A 347 ALA A 350 GLU A 353 SITE 2 AC1 14 LEU A 387 ARG A 394 GLY A 521 LEU A 525 SITE 3 AC1 14 MET A 528 LYS A 529 CYS A 530 EDO A 603 SITE 4 AC1 14 HOH A 710 HOH A 748 SITE 1 AC2 8 SER A 381 ALA A 382 TRP A 383 LEU A 384 SITE 2 AC2 8 GLU A 385 SER A 518 MET A 522 HOH A 751 SITE 1 AC3 5 ALA A 350 ASP A 351 TRP A 383 F3D A 601 SITE 2 AC3 5 HOH A 758 SITE 1 AC4 2 GLU A 323 TRP A 393 SITE 1 AC5 6 HIS A 476 LEU A 479 ASP A 480 GLN A 506 SITE 2 AC5 6 LEU A 509 HOH A 717 CRYST1 58.735 58.735 274.814 90.00 90.00 120.00 P 65 2 2 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017026 0.009830 0.000000 0.00000 SCALE2 0.000000 0.019659 0.000000 0.00000 SCALE3 0.000000 0.000000 0.003639 0.00000